With tailor-made nanocarriers, we will set new standards for the targeted, efficient and low-risk use of active pharmaceutical ingredients and other highly potent substances for medical and life science applications.
OUR VISION
We save human lives
by targeted use of highly potent substances
We rethink therapy
via tailor-made nanocarriers for efficiency and safety
We treat the untreatable
e.g. septic liver failure
NEWS
26th January 2026
BMFTR RESEARCH CAMPUS INITIATIVE: JOINT PROJECT APPROVED
In fall 2025, the jury of the BMFTR Research Campus Initiative approved the third phase of the InfectoGnostics Research Campus, with SmartDyeLivery as an industry partner. Since October 2025, the campus partners have been working on seven new lead projects for diagnostic solutions of the future.
At the kick-off on January 14, 2026, at the Center for Applied Research in Jena, SmartDyeLivery and its partners provided an insight into the planned research work. ...
Together with Jena University Hospital (UKJ), we are developing a novel nanotherapy for steatohepatitis, an inflammatory form of fatty liver disease, as part of the RESOLVE joint project. Targeted nanocarriers will be used to deliver drugs directly to liver and immune cells in order to slow down inflammation, metabolic disorders, and fibrosis at an early stage. ...
On Friday evening, 21 November 2025, the popular science evening took place once again at the Talschule in Jena. The event is held every two years at this primary school since 2013 and inspires children, parents and teachers alike – with fascinating insights into the world of science. Four dedicated employees demonstrated their commitment at one of 30 stations: with mega particles, colourful reactions and many ‘aha’ moments...
